Traders should watch for ESMO presentation on July 4, 2026, and any updates on NMPA approval timeline. Given priority review status, approval could come in H2 2026. The 42.5% ORR in a heavily pretreated population is clinically meaningful and supports a differentiated profile vs. existing FGFR inhibitors.
HCM drugs
HCM drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 25 $10.29entry
- T+1 · 5mo ago −1.17%α −0.44% · $10.17
- T+5 · 5mo ago +4.76%α +3.20% · $10.78
- T+20 · 4mo ago +6.51%α +5.98% · $10.96
- T+60 · 8w ago +32.85%α +29.12% · $13.67
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
HUTCHMED reported pivotal Phase II data for fanregratinib in FGFR2-fusion intrahepatic cholangiocarcinoma, showing a 42.5% ORR (primary endpoint met) and a manageable safety profile. The NDA has already been accepted with priority review by China's NMPA since December 2025, de-risking the regulatory path. This is a clear positive catalyst for a mid-cap biotech with an 88% bullish analyst consensus.
Key Facts
- Phase II registration trial (NCT04353375) met primary endpoint: IRC-assessed ORR of 42.5% (95% CI: 30.0%-53.6%)
- Median progression-free survival (PFS) of 6.9 months; median overall survival (OS) of 16.6 months
- Disease control rate (DCR) of 83.9% (95% CI: 74.5%-90.9%)
- NDA for fanregratinib in advanced ICC accepted and granted priority review by China NMPA in December 2025
- Fanregratinib is wholly owned by HUTCHMED worldwide with no out-licensed ex-China rights
- Treatment discontinuation due to drug-related AEs limited to 2.2%; no treatment-related deaths
- Data presented at ESMO Gastrointestinal Cancers Congress (July 2026) in a rapid oral session
Financial Impact
Fanregratinib targets a defined biomarker (FGFR2 fusion) in ICC, where approved FGFR inhibitors (Pemigatinib, Infigatinib) have shown similar sales trajectories (~$200-400M peak for second-to-market FGFR drugs). HUTCHMED retains global rights, but near-term revenues (ex-China partnership potential or China launch) are not quantifiable from this filing.
Risk Factors
- Fanregratinib is not yet approved in any jurisdiction; NMPA priority review is no guarantee of approval
- Grade ≥3 AE rate of 48.3% is notable, though discontinuation rate is low (2.2%)
- Commercial success depends on pricing/reimbursement in China and potential ex-China partnership terms
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001648257-26-000041 |
| Document: hcm-20260625x6k.htm | 0001648257-26-000041 |
| Document: 0001648257-26-000041-index-headers.html | 0001648257-26-000041 |
| Document: 0001648257-26-000041-index.html | 0001648257-26-000041 |
| Document: 0001648257-26-000041.txt | 0001648257-26-000041 |
Track record
33 reports on HCM
7 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +38.35% at T+60 after the Jun 25, 2026 report. 17 of 22 went positive at some point.
Filters
- Nov 15, 20261d ago Press Release Neutral 4/10 Entry $14.90 Now $14.73 −1.14% settles Feb 12
- Nov 5, 202611d ago 6-K Bullish 5/10 Entry $14.20 Now $14.73 +3.73% settles Feb 3
- Nov 2, 202614d ago 6-K Bullish 6/10 Entry $13.27 Now $14.73 +11.00% settles Jan 29
- Nov 2, 202615d ago Press Release Bullish 6/10 Entry $13.08 Now $14.73 +12.61% settles Feb 1
- Oct 29, 202618d ago 6-K Neutral 4/10 Entry $13.59 Now $14.73 +8.39% settles Jan 27
- Oct 27, 202620d ago 6-K Neutral 2/10 Entry $13.80 Now $14.73 +6.74% settles Jan 25
- Oct 26, 202621d ago 6-K Bullish 6/10 Entry $14.27 Now $14.73 +3.22% settles Jan 22
- Oct 26, 202621d ago Press Release Bullish 7/10 Entry $14.27 Now $14.73 +3.22% settles Jan 22
- Oct 26, 202622d ago Press Release Bullish 7/10 Entry $13.80 Now $14.73 +6.74% settles Jan 25
- Oct 21, 202626d ago 6-K Bullish 7/10 Entry $14.37 Now $14.73 +2.51% settles Jan 19
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers